selective factor Xia serine protease inhib.
oral, phase II, cardiovascular
from opt. of previous macrocyclic FXIa inh.
Journal of Medicinal Chemistry
Bristol Myers Squibb
The BMS factor XIa inhibitor, milvexian (BMS-986177), is an oral antithrombotic with a Ki of 0.11 nM. A member of this macrocyclic series was previously highlighted as one of 2020’s Molecules of…